Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

Inclusion Criteria Concurrent Medication: Allowed: Aerosolized pentamidine. Patients must have the following: - Seropositive for HIV-1 (ELISA assay) confirmed by Western blot. HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patients' peripheral blood monocytes (PBMC) on two separate occasions. Voluntarily sign consent. Patients with HIV "wasting syndrome" are included. Prior Medication: Allowed: Aerosolized pentamidine. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: AIDS as defined by the CDC (except for those with HIV "wasting syndrome"). Significant hepatic disease. Thrombocytopenia. Hypersensitivity to thymopentin. Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products. Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry. Patients with the following are excluded: AIDS as defined by the CDC (except for those with HIV "wasting syndrome"). Significant hepatic disease. Thrombocytopenia. Hypersensitivity to thymopentin. Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products. Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry. Prior Medication: Excluded within 30 days of study entry: Immunomodulatory or experimental therapy. Excluded within 90 days of study entry: Zidovudine (AZT). Intravenous drug abuse.